At the same time taking multiple daily doses of rosuvastatin pharmacokinetic parameters are not changed.
No specific antidote. If necessary spend symptomatic masteron steroid therapy, necessary to monitor liver function and activity. Hemodialysis is not effective.
Interaction with other drugs
With simultaneous use of rosuvastatin and cyclosporine of rosuvastatin was on average 7 times higher than the value that was observed in healthy volunteers, the plasma concentration of cyclosporin is not changed. Simultaneous use leads to an increase in plasma concentrations in plasma rosuvastatin 11 times.
Starting therapy rosuvastatin or increasing doses in patients receiving both vitamin K antagonists (e.g. warfarin), may lead to an increase in the prothrombin time . Cancel rosuvastatin or reducing the dose may reduce (in such cases, we recommend monitoringMHO).
Concomitant use of rosuvastatin and ezetimibe did not reveal any changes in of any one drug. However, their pharmacodynamic interaction and the occurrence of adverse effects can not be excluded.
Concomitant use of rosuvastatin and gemfibrozil increases in masteron steroidof rosuvastatin. According to special studies relevant pharmacokinetic interaction with fenofibrate is not indicated, however, may have different pharmacodynamic interaction. Gemofibrozil, fenofibrate, fibrates and other lipid-lowering doses of nicotinic acid, increase the risk of myopathy, when applied simultaneously with inhibitors reductase. Probably due to the fact that inhibitors may cause myopathy and when used in monotherapy.
Although the exact mechanism of the interaction with rosuvastatin unknown protease inhibitors, their use can cause simultaneous amplification rosuvastatin persistent action. The pharmacokinetic studies in healthy volunteers, the combined use of 20 mg of rosuvastatin, and combinations of protease inhibitors (400 mg lopinavir / ritonavir 100 mg) produced about two and five-fold increase , respectively. Therefore, the simultaneous use of rosuvastatin and protease inhibitors in the treatment of patients with human immunodeficiency virus masteron steroidis not recommended.
Simultaneous use of rosuvastatin and antacid suspensions containing aluminum or magnesium hydroxide, results in decreased plasma rosuvastatin concentrations of about 50%. This effect is less pronounced, if antacids applied 2 hours after receiving rosuvastatin. The clinical significance of this interaction has not been studied.
Concomitant use of rosuvastatin and erythromycin leads to a decrease in of rosuvastatin rosuvastatin by 30%, probably due to increased intestinal motility caused by taking erythromycin. Concomitant use of rosuvastatin and oral contraceptives increases the of ethinyl estradiol and norgestrel of 26% and 34%, respectively. This increase in plasma concentrations should be considered when selecting the dose of oral contraceptives during treatment with rosuvastatin.
On the basis of studies of the interaction of rosuvastatin with digoxin clinically significant interactions have been identified.
The results of in vivo studies and in vitro studies have shown that rosuvastatin is neither an inhibitor nor an inducer of cytochrome system isoenzymes . Furthermore, rosuvastatin is poor substrate for these isoenzymes. There were no clinically significant interaction between rosuvastatin and fluconazole, and ketoconazole (. The combined use of rosuvastatin and itraconazole increases the masteron steroidof rosuvastatin by 28% (clinically insignificant). Thus it is not expected interaction associated with the cytochrome P450 system.